The Molecular Basis of Leukemia
Open Access
- 1 January 2004
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2004 (1), 80-97
- https://doi.org/10.1182/asheducation-2004.1.80
Abstract
Major strides have been made in our understanding of the molecular basis of adult and pediatric leukemias. More than one hundred disease alleles have been identified and characterized in cell culture and murine models of leukemia. In some instances, molecularly targeted therapies have been developed based on these insights that are currently in clinical trials, such as small molecule inhibitors of FLT3. In addition, it has recently been appreciated that, as with normal hematopoiesis, there is a hierarchical organization among leukemic cells that includes a rare population of leukemic stem cells that have properties of self-renewal. Understanding the characteristics of these leukemic stem cells may provide new insights into leukemia therapies that target self-renewal pathways. In Section I, Dr. Craig Jordan reviews the data that supports the existence of a “leukemia stem cell.” He provides an overview of the functional properties of leukemic stem cells, their relationship to hematopoietic stem cells, and the relevance of leukemic stem cells in other human malignancies including solid tumors. He briefly discusses what is known of the pathways that regulate properties of self-renewal. Dr. Gary Gilliland provides an overview of the genetics of adult leukemias in Section II and ongoing genome-wide strategies for discovery of new disease alleles. He describes the clinical and therapeutic implications of these findings and provides examples of bench-to-bedside translation of molecularly targeted therapies for AML, including the use of FLT3 inhibitors. In Section III, Dr. Carolyn Felix reviews recent advances in our understanding of the genetics and therapy of pediatric leukemias. She provides an overview of leukemias that are common in pediatric malignancies but rarely observed in adults, including the TEL-AML1 (ETV6-RUNX1) fusion associated with pediatric B-cell ALL, the OTT-MAL fusion associated with infant megakaryoblastic leukemia, PTPN11 mutations in juvenile myelomonocytic leukemia, and MLL fusion genes in leukemogenesis, among others.Keywords
This publication has 77 references indexed in Scilit:
- Protracted postnatal natural histories in childhood leukemiaGenes, Chromosomes and Cancer, 2004
- Quinolone Action against Human Topoisomerase IIα: Stimulation of Enzyme-Mediated Double-Stranded DNA CleavageBiochemistry, 2003
- Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and childrenBlood, 2002
- Molecular genetics of human leukemias: New insights into therapySeminars in Hematology, 2002
- Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemiaLeukemia, 2002
- Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cellsEnvironmental and Molecular Mutagenesis, 2002
- Recurrence of OTT–MAL fusion in t(1;22) of infant AML‐M7Genes, Chromosomes and Cancer, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Rapid evaluation of topoisomerase inhibitors: Caffeine inhibition of topoisomerases in vivoTeratogenesis, Carcinogenesis, and Mutagenesis, 1990